Comparative Pharmacology
Head-to-head clinical analysis: EZALLOR SPRINKLE versus PREVACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EZALLOR SPRINKLE versus PREVACID.
EZALLOR SPRINKLE vs PREVACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
None Documented
None Documented
Terminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments.
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%.
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor